Page 116 - GTM-4-2

Global Translational Medicine Platelet aggregation inhibition by 2-isoxazolines

Writing – original draft: Mikalai M. Kauhanka, Svetlana N. 2002;99(7):2612-2614.
Borisevich, Stanislava V. Glinnik doi: 10.1182/blood.v99.7.2612
Writing – review & editing: Mikalai M. Kauhanka,
Marharita E.Parkhach 5. Ruggeri ZM. Mechanisms initiating platelet thrombus
formation. Thromb Haemost. 1997;78(1):611-616.
Ethics approval and consent to participate doi: 10.1055/s-0038-1657598

This research involved the use of platelet-rich plasma from 6. Gutiérrez M, Amigo J, Fuentes E, Palomo I, Astudillo L.
healthy donors. All donors gave written voluntary consent Synthetic isoxazole as antiplatelet agent. Platelets.
to participate in the study. 2014;25(4):234-238.
Consent for publication doi: 10.3109/09537104.2013.807335
7. Xue CB, Roderick J, Mousa S, Olson RE, DeGrado WF.
Donors consented to the publication of their data. Synthesis and antiplatelet effects of an isoxazole series of
Availability of data glycoprotein IIb/IIIa antagonists. Bioorg Med Chem Lett.
1998;8(24):3499-3504.
Data will be made available upon request to the doi: 10.1016/s0960-894x(98)00637-4
corresponding author.
8. Yogesh W, Pravin M, Pramod K. Application, reactivity
References and synthesis of isoxazole derivatives. Mini-Rev Org Chem.
2021;18(1):55-77.
1. Jennings LK. Mechanisms of platelet activation: Need
for new strategies to protect against platelet-mediated doi: 10.2174/1570193x17999200511131621
atherothrombosis. Thromb Haemost. 2009;102(2):248-257. 9. Shanshan L, Yiou M, Luchen J, Xueyan Y, Wei Z, Yunfei D.
doi: 10.1160/TH09-03-0192 Oxazole and isoxazole-containing pharmaceuticals: Targets,
pharmacological activities, and their SAR studies. RSC Med
2. Angiolillo DJ, Capodanno D, Goto, S. Platelet thrombin Chem. 2025;16(4):1461-1469.
receptor antagonism and atherothrombosis. Eur Heart J.
2010;31(1):17-28. doi: 10.1039/D4MD00777H
doi: 10.1093/eurheartj/ehp504 10. Mohan K, Vikul K, Meenakshi S. A review of isoxazole
biological activity and present synthetic techniques. Int J
3. Fuentes QE, Fuentes QF, Andrés V, Pello OM, Font de Pharm Chem Anal. 2024;11(4):307-317.
Mora J, Palomo GI. Role of platelets as mediators that link
inflammation and thrombosis in atherosclerosis. Platelets. doi: 10.18231/j.ijpca.2024.045
2013;24(4):255-262. 11. Vinholt PJ, Frederiksen H, Hvas AM, Sprogøe U, Nielsen, C.
doi: 10.3109/09537104.2012.690113 Measurement of platelet aggregation, independently of
patient platelet count: A flow-cytometric approach. J Thromb
4. Viallard JF, Solanilla A, Gauthier B, et al. Increased
soluble and platelet-associated CD40 ligand in essential Haemost. 2017;15(6):1191-1202.
thrombocythemia and reactive thrombocytosis. Blood. doi: 10.1111/jth.13675

Volume 4 Issue 2 (2025) 108 doi: 10.36922/gtm.8147